Astrazeneca Covid Vaccine
- All
- News
- Videos
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Covishield Side Effects: Doctors' Group Urges Centre To Review All Covid Vaccines
In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its Covid vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the safety of the Covishield vaccine.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
AstraZeneca Drops Covid Vaccine Weeks After Rare Side Effect Report
AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine, days after it was reported that the British pharmaceutical company admitted that the jab can cause rare side effects.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
Fact Check: Are Indians Who Got Covishield Vaccine Susceptible To TTS?
AstraZeneca, which developed and manufactured the Covid vaccine Covishield. recently admitted that the vaccine could cause TTS (a condition that may cause blood clots and low platelet count) as a side effect in some people.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
AstraZeneca Makes Big U-Turn, Admits Covishield Can Cause Rare Side Effects
British pharma giant AstraZeneca has admitted that its Covid vaccine can cause rare side effects, The Telegraph (UK) has reported.
-
AstraZeneca Covid Jab Linked To Higher Risk Of Rare Blood Clot, Finds Study
AstraZeneca's Covid vaccine has been linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab, a large international study said on Thursday.
-
High Hopes For Nasal Covid Vaccines Despite "Disappointing" Trial
Nasal vaccines could still be a powerful future weapon in the fight against Covid-19 despite "disappointing" recent trial results for an AstraZeneca spray, experts say.
-
AstraZeneca Nasal Spray Vaccine For Covid Fizzles In Small, Early Trial
AstraZeneca Plc's ambitions for developing an easier formulation of its Covid-19 vaccine -- one that might help curb contagion as well -- suffered a setback Monday as the nasal spray failed in an early test.
-
AstraZeneca Claims Positive Medicine Trial For "Severe" Covid
A treatment for people at risk of death from coronavirus has revealed good results in a late-stage trial, its maker AstraZeneca announced Wednesday.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Covishield Side Effects: Doctors' Group Urges Centre To Review All Covid Vaccines
In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its Covid vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the safety of the Covishield vaccine.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
AstraZeneca Drops Covid Vaccine Weeks After Rare Side Effect Report
AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine, days after it was reported that the British pharmaceutical company admitted that the jab can cause rare side effects.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
Fact Check: Are Indians Who Got Covishield Vaccine Susceptible To TTS?
AstraZeneca, which developed and manufactured the Covid vaccine Covishield. recently admitted that the vaccine could cause TTS (a condition that may cause blood clots and low platelet count) as a side effect in some people.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
AstraZeneca Makes Big U-Turn, Admits Covishield Can Cause Rare Side Effects
British pharma giant AstraZeneca has admitted that its Covid vaccine can cause rare side effects, The Telegraph (UK) has reported.
-
AstraZeneca Covid Jab Linked To Higher Risk Of Rare Blood Clot, Finds Study
AstraZeneca's Covid vaccine has been linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab, a large international study said on Thursday.
-
High Hopes For Nasal Covid Vaccines Despite "Disappointing" Trial
Nasal vaccines could still be a powerful future weapon in the fight against Covid-19 despite "disappointing" recent trial results for an AstraZeneca spray, experts say.
-
AstraZeneca Nasal Spray Vaccine For Covid Fizzles In Small, Early Trial
AstraZeneca Plc's ambitions for developing an easier formulation of its Covid-19 vaccine -- one that might help curb contagion as well -- suffered a setback Monday as the nasal spray failed in an early test.
-
AstraZeneca Claims Positive Medicine Trial For "Severe" Covid
A treatment for people at risk of death from coronavirus has revealed good results in a late-stage trial, its maker AstraZeneca announced Wednesday.
